Login to Your Account


Regeneron's AMD Eylea Push Makes Inroads: Diabetics Next?

By Randy Osborne
Staff Writer

Tuesday, August 6, 2013
The possibility of rebates attached to Regeneron Pharmaceuticals Inc.'s age-related macular degeneration (AMD) drug Eylea (aflibercept) – such as those offered by the maker of competitor Lucentis – was one of a handful of issues raised by analysts during the company's second quarter earnings call, but CEO Leonard Schleifer declined to tip his hand.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription